Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dorzolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 18/20 | 0.98 |
| ▸ | CA1 | P00915 | 3/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | CA3 | P07451 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 1/20 | 0.98 |
| ▸ | CA4 | P22748 | 1/20 | 0.98 |
| ▸ | CA6 | P23280 | 1/20 | 0.98 |
| ▸ | CA5A | P35218 | 1/20 | 0.98 |
| ▸ | CA7 | P43166 | 1/20 | 0.98 |
| ▸ | CA9 | Q16790 | 1/20 | 0.98 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.98 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.98 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dorzolamide SCHEMBL28388851 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL15545592 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL3314050 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4525137 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4455530 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12223216 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12874119 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL3306381 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL9914275 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL9914274 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1893 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4626373-A2 | BIO-ERODIBLE OCULAR IMPLANTS FOR TREATMENT OF CONDITIONS OF THE EYE | Sight Sciences, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4558136-A1 | PRESERVATIVE-FREE OPHTHALMIC COMPOSITION COMPRISING AN ANTIGLAUCOMA AGENT | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2025-05-28 | — | — | EP | claimed |
| EP-4552693-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | Sustain Holdings, LLC (US) | 2025-05-14 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2025040941-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING DORZOLAMIDE, METHODS FOR THEIR PREPARATION, AND FOR THEIR USE | SOPHIA HOLDINGS S.A. DE C.V. (MX) | 2025-02-27 | — | — | WO | claimed |
| WO-2025004579-A1 | OPHTHALMIC COMPOSITION | 株式会社ニデック | 2025-01-02 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12029682-B2 | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume ophthalmic administration | EYENOVIA, INC. (US) | 2024-07-09 | — | — | US | claimed |
| CN-1407903-A | Combined agent for treating glaucoma | SANKYO CO (JP) | 2003-04-02 | — | — | CN | claimed |
| US-20030040529-A1 | Combined agents for treatment of glaucoma | SANKYO COMPANY, LIMITED (JP) | 2003-02-27 | — | — | US | claimed |
| EP-0932389-B1 | OPHTHALMIC COMPOSITIONS CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND XANTHAN GUM | MERCK SHARP & DOHME CHIBRET SN (FR) | 2002-09-04 | — | — | EP | claimed |
| EP-1234582-A1 | CONCOMITANT DRUGS FOR TREATING GLAUCOMA | Sankyo Company, Limited (JP) | 2002-08-28 | — | — | EP | claimed |
| US-6264935-B1 | HYPOTENSIVE AGENT FOR EYES | LABORATOIRES MSD - CHIBRET (FR) | 2001-07-24 | — | — | US | claimed |
| US-6248735-B1 | TOPICAL SYNERGISTIC MIXTURE OF OCULAR HYPOTENSIVE AGENTS 5,6-DIHYDRO-4-ETHYLAMINO-6-METHYL-4H-THIENO-(2,3-B)THIOPYRAN-2 -SULFONAMIDE-7,7-DIOXIDE OR SALT AND TIMOLOL OR ITS MALEATE SALT | MERCK & CO., INC. | 2001-06-19 | — | — | US | claimed |
| US-6156785-A | Method for increasing oxygen tension in the optic nerve and retina | MERCK SHARP & DOHME B.V. (NL) | 2000-12-05 | — | — | US | claimed |
| EP-1024810-A1 | METHOD FOR OPTIMIZING RETINAL AND OPTIC NERVE HEALTH | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999000133-A1 | METHOD FOR OPTIMIZING RETINAL AND OPTIC NERVE HEALTH | MERCK & CO., INC. (US) | 1999-01-07 | — | — | WO | claimed |
| US-5620970-A | STABLE MIXTURE CONTAINING ENZYME INHIBITOR AND (POLY)ETHOXYLATED CASTOR OIL; GLAUCOMA, OCCULAR HYPERTENSION | ALCON LABORATORIES, INC. (US) | 1997-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040529-A1 | Combined agents for treatment of glaucoma | PTGIR, AGTR2, AGT | CA2 11/4885CA1 218/4885CA12 212/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | CA2 1945/4885CA1 1436/4885CA12 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.